CRL Stock Analysis — Charles River Laboratories
Sector: Healthcare
AI Verdict
You're paying a slight premium at 23.3x forward earnings for a moat built on sticky pharma relationships, but with flat growth and a hot RSI, the numbers don't leave much margin for disappointment.
Competitive Moat
Charles River Laboratories provides essential preclinical research services for drug developers, with deep expertise in regulated animal testing and specialized facilities that are costly and time-consuming to replicate. Its embedded relationships with pharma clients and regulatory know-how create high switching costs and recurring demand.
Summary
The stock is running hot after a 73.43% one-year gain despite nearly flat revenue growth.
Where It Stands
CRL is up 73.43% in the past year, trades at 23.3x forward earnings (just above the healthcare median of 22x), and has an RSI of 69.3, signaling elevated pullback risk.
Key Metrics
- RSI: 69.3 — Near Overbought
- Forward P/E: 23.3x
- Revenue Growth: +0.0%
- Market Cap: $12.6B
- 1-Year Return: 73.43%
- 52-Week High: $267.99
- 52-Week Low: $144.26
Analyst Consensus
15 Buy · 7 Hold · 0 Sell (22 analysts)
Bull Case
The 23.3x forward P/E is only modestly above the sector median, which could be justified if the company's entrenched client relationships drive a rebound from its current 0.1% revenue growth.
Bear Case
With an RSI of 69.3 and a forward P/E above the sector median, a pullback to sector-average valuation would mean a roughly 6%–7% drop if growth doesn't accelerate soon.
Catalyst to Watch
Watch for the next earnings call: any sign of revenue reacceleration above the current 0.1% YoY could support the premium multiple.